Martin Shkreli on Drug Pricing, Prison, and the Fraud That Shook Pharma — The Doctors’ Lounge

Episode Summary

Anish Koka and Anthony DiGiorgio sit down with Martin Shkreli — the former hedge fund manager and pharma executive best known for the 2015 Daraprim price increase and his subsequent prison sentence — for a wide-ranging conversation on drug pricing, patent law, and the state of the pharmaceutical industry. Shkreli walks through his path from a teenage hedge fund intern to founding Retrophin and Turing Pharmaceuticals, defends orphan drug economics and the Orphan Drug Act's seven-year exclusivity window, and argues that patent terms haven't kept pace with the realities of modern drug development. The conversation turns to the Chemocentrics/Amgen scandal — in which trial data for a rare vasculitis drug was allegedly unblinded, manipulated, and relocked to manufacture statistical significance — which Shkreli calls one of the worst frauds in the history of medicine. The episode closes with discussion of the Sarepta/DMD approval controversy, the limits of randomized trials in surgery and rare disease, AI's parallels to neuroscience, and the state of media coverage of the FDA.

Chapter Markers

00:00 Intro and Martin Shkreli's backstory

02:40 Origin story: from hedge fund to founding drug companies

07:58 The Daraprim price increase and Shkreli's pricing philosophy

17:14 What it actually takes to bring a drug to market

35:25 The case for the pharmaceutical industry

38:00 The Orphan Drug Act and patent exclusivity

57:31 The Chemocentrics scandal: manipulated trial data at Amgen

1:22:09 Vinay Prasad, Sarepta, and the DMD approval fights

1:34:35 Neurosurgery, clinical trials, and the limits of RCTs

1:37:30 AI, neural networks, and the future of psychiatric drugs

1:40:40 Cardiovascular disease and LDL lowering